Cancer Drugs
Search documents
Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy?
Yahoo Finance· 2026-01-31 17:35
Group 1 - Johnson & Johnson (NYSE: JNJ) is recognized as one of the most profitable healthcare stocks, with TD Cowen raising its price target from $222 to $250, indicating a potential upside of approximately 14% [1] - The company's fourth quarter results exceeded market estimates, reporting $24.6 billion in revenue, which has led several analysts to update their outlooks positively [3] - TD Cowen anticipates that Johnson & Johnson's Pharmaceutical and Medical Devices segments will continue to grow, uplifting consensus revenue and EPS forecasts [2] Group 2 - Johnson & Johnson operates in two main segments: Innovative Medicine and MedTech, providing healthcare products globally since its founding in 1886 [4] - BofA Securities has also slightly increased its price target for Johnson & Johnson from $220 to $221, maintaining a Neutral rating, citing solid financial results driven by growth factors, particularly currency movements [3]
Analysts Turn More Constructive on Johnson & Johnson (JNJ) Heading Into 2026
Yahoo Finance· 2026-01-16 19:17
Company Overview - Johnson & Johnson (NYSE: JNJ) is recognized as one of the most profitable US stocks to buy, with a focus on innovative medicines and medical technologies [1][4] - The company has a diverse clientele, including retailers, wholesalers, healthcare professionals, and hospitals [4] Price Target Adjustments - Bernstein raised the price target for Johnson & Johnson to $208 from $193 while maintaining a 'Market Perform' rating [1] - Stifel also increased its price target for Johnson & Johnson to $205 from $190, keeping a 'Hold' rating [3] Recent Acquisitions - Johnson & Johnson completed the acquisition of Halda Therapeutics for approximately $3.05 billion on December 29, 2025 [3] - The Halda acquisition is expected to be dilutive to Johnson & Johnson's adjusted earnings per share by a total of $0.20, impacting $0.10 in both 2025 and 2026 [4] Market Performance and Outlook - U.S. healthcare stocks, including Johnson & Johnson, have shown improved performance following a low point in September 2025, with a more favorable outlook for 2026 [2]